Loading
Rheumatologist who is Dean of Medicine at the University of Hong Kong, the academic partner of Queen Mary Hospital, and formerly chief of the hospital's Department of Medicine.
Professor Chak-sing Lau, BBS, JP, is the forty-first Dean of Medicine at The University of Hong Kong, whose LKS Faculty of Medicine is the teaching and research partner of Queen Mary Hospital, and is also interim Vice-President and Pro-Vice-Chancellor (Health). He holds the Daniel CK Yu Professorship in Rheumatology and Clinical Immunology and previously served as Chairperson of the Department of Medicine, Chief of Service in Medicine at Queen Mary Hospital and President of the Hong Kong Academy of Medicine. He is regarded as a pioneer of rheumatology in Hong Kong and founded the Hong Kong Arthritis and Rheumatism Foundation in 2001.
| Title | Journal | Year |
|---|---|---|
| Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial | The Lancet | 2020 |
| Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis | New England Journal of Medicine | 2000 |
| Definition and initial validation of a Lupus Low Disease Activity State (LLDAS) | Annals of the Rheumatic Diseases | 2016 |
These papers come from a Europe PMC search on the author's name and institution, taking the most cited articles.
Shares New England Journal of Medicine and the tags leadership, clinician-scientist.
Shares New England Journal of Medicine and the tags leadership, clinician-scientist.
Shares The Lancet, New England Journal of Medicine and the tag leadership.
Shares The Lancet and the tag leadership.
Shares the tags leadership, clinician-scientist.
Shares the tags leadership, clinician-scientist.
Shares the tags leadership, clinician-scientist.
Shares the tags leadership, clinician-scientist.